Stockreport

REGENXBIO Receives FDA Fast Track Designation for RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I

REGENXBIO Inc.  (RGNX) 
Last regenxbio inc. earnings: 2/26 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.regenxbio.com